fbpx

genetic diseases

A negative anti-amyloid drug trial results show that crenezumab is not superior to placebo for genetically high-risk Alzheimer’s patients

Top-line study results were released earlier this year. However, the researchers presented additional findings and perspectives at the Alzheimer’s Association International Conference 2022. The investigational anti-amyloid monoclonal antibody crenezumab (Genentech) is not superior to a placebo for change in cognition, brain imaging, or biomarker outcomes in individuals who are at genetically high risk for Alzheimer’s disease (AD), […]

A low dose of ketamine is safe and effective for treating children with ADNP syndrome

The research was led by researchers from the Seaver Autism Center for Research and Treatment at Mount Sinai and published online in Human Genetics and Genomic Advances. Ketamine was approved in the United States in 1970. Studies in animal models suggest that low-dose ketamine may be neuroprotective and increase the expression of the ADNP gene. […]

A new prenatal test can speed up and save money when it comes to chromosomal anomalies

Details about the test which are awaiting authorization from the New York State Department of Health before it can be offered to Columbia patients and its performance was published in the New England Journal of Medicine. Prenatal genetic testing are currently available, but they are expensive and take days to weeks to complete; this adds […]

Scroll to top